Essec\Faculty\Model\Contribution {#2233
  #_index: "academ_contributions"
  #_id: "10119"
  #_source: array:26 [
    "id" => "10119"
    "slug" => "economic-implications-of-non-adherence-to-haart-in-hiv-patients"
    "yearMonth" => "2006-02"
    "year" => "2006"
    "title" => "Economic implications of non-adherence to HAART in HIV patients"
    "description" => "LAMIRAUD, K. et MOATTI, J.P. (2006). Economic implications of non-adherence to HAART in HIV patients. <i>Expert Opinion on Pharmacotherapy</i>, 7(2), pp. 135-143."
    "authors" => array:3 [
      0 => array:3 [
        "name" => "LAMIRAUD Karine"
        "bid" => "B00278040"
        "slug" => "lamiraud-karine"
      ]
      1 => array:1 [
        "name" => "MOATTI J"
      ]
      2 => array:1 [
        "name" => "P."
      ]
    ]
    "ouvrage" => ""
    "keywords" => array:4 [
      0 => "cost analysis"
      1 => "drug valuation"
      2 => "economic analysis"
      3 => """
        highly active antiretroviral treatment -\n
        microeconomics
        """
    ]
    "updatedAt" => "2021-07-13 14:31:27"
    "publicationUrl" => null
    "publicationInfo" => array:3 [
      "pages" => "135-143"
      "volume" => "7"
      "number" => "2"
    ]
    "type" => array:2 [
      "fr" => "Articles"
      "en" => "Journal articles"
    ]
    "support_type" => array:2 [
      "fr" => "Revue professionnelle"
      "en" => "Professional journal"
    ]
    "countries" => array:2 [
      "fr" => null
      "en" => null
    ]
    "abstract" => array:2 [
      "fr" => """
        Until now, the economic implications of nonadherence to drug therapies\n
        have been mostly assessed in a cost perspective and understood as the\n
        impact of nonadherence behaviours on the cost-effectiveness ratios of particular\n
        therapies. In HIV disease, some modelling approaches have suggested\n
        that high adherence levels might improve the cost-effectiveness of\n
        highly active antiretroviral treatment regimens. However, there is an urgent\n
        need for research directly observing and measuring the costs of nonadherence\n
        behaviours. In addition to this cost perspective, the authors argue that\n
        the economic impact of nonadherence should also be studied in a microeconomic\n
        ¿ patient-oriented ¿ perspective. Major implications of this microeconomic\n
        perspective are drawn. First, the microeconomic approach highlights\n
        that nonadherence may often be a rational choice of the patient, thus suggesting\n
        new ways for improving adherence. Second, it implies that the\n
        adherence behaviour can be interpreted as an indicator of patients¿ subjective\n
        valuation of highly active antiretroviral treatment therapies; in particular,\n
        higher levels of adherence are associated with higher patient wellbeing.\n
        Third, it shows that the adherence behaviour cannot be regarded as\n
        an exogenous variable when the impact of adherence on health outcome\n
        or on cost-effectiveness ratios is studied, thus requiring the use of specific\n
        statistical or econometric methods.
        """
      "en" => """
        Until now, the economic implications of nonadherence to drug therapies\n
        have been mostly assessed in a cost perspective and understood as the\n
        impact of nonadherence behaviours on the cost-effectiveness ratios of particular\n
        therapies. In HIV disease, some modelling approaches have suggested\n
        that high adherence levels might improve the cost-effectiveness of\n
        highly active antiretroviral treatment regimens. However, there is an urgent\n
        need for research directly observing and measuring the costs of nonadherence\n
        behaviours. In addition to this cost perspective, the authors argue that\n
        the economic impact of nonadherence should also be studied in a microeconomic\n
        ¿ patient-oriented ¿ perspective. Major implications of this microeconomic\n
        perspective are drawn. First, the microeconomic approach highlights\n
        that nonadherence may often be a rational choice of the patient, thus suggesting\n
        new ways for improving adherence. Second, it implies that the\n
        adherence behaviour can be interpreted as an indicator of patients¿ subjective\n
        valuation of highly active antiretroviral treatment therapies; in particular,\n
        higher levels of adherence are associated with higher patient wellbeing.\n
        Third, it shows that the adherence behaviour cannot be regarded as\n
        an exogenous variable when the impact of adherence on health outcome\n
        or on cost-effectiveness ratios is studied, thus requiring the use of specific\n
        statistical or econometric methods.
        """
    ]
    "authors_fields" => array:2 [
      "fr" => "Economie"
      "en" => "Economics"
    ]
    "indexedAt" => "2024-11-21T11:21:49.000Z"
    "docTitle" => "Economic implications of non-adherence to HAART in HIV patients"
    "docSurtitle" => "Articles"
    "authorNames" => "<a href="/cv/lamiraud-karine">LAMIRAUD Karine</a>, MOATTI J, P."
    "docDescription" => "<span class="document-property-authors">LAMIRAUD Karine, MOATTI J, P.</span><br><span class="document-property-authors_fields">Economie</span> | <span class="document-property-year">2006</span>"
    "keywordList" => """
      <a href="#">cost analysis</a>, <a href="#">drug valuation</a>, <a href="#">economic analysis</a>, <a href="#">highly active antiretroviral treatment -\n
      microeconomics</a>
      """
    "docPreview" => "<b>Economic implications of non-adherence to HAART in HIV patients</b><br><span>2006-02 | Articles </span>"
    "docType" => "research"
    "publicationLink" => "<a href="#" target="_blank">Economic implications of non-adherence to HAART in HIV patients</a>"
  ]
  +lang: "fr"
  +"_type": "_doc"
  +"_score": 8.953466
  +"parent": null
}